keyword
MENU ▼
Read by QxMD icon Read
search

LAR Exenatide

keyword
https://www.readbyqxmd.com/read/27717130/glucagon-like-peptide-1-receptor-agonists-compared-with-basal-insulins-for-the-treatment-of-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis
#1
Sonal Singh, Eugene E Wright, Anita Ym Kwan, Juliette C Thompson, Iqra A Syed, Ellen E Korol, Nathalie A Waser, Maria B Yu, Rattan Juneja
AIMS: Since 2005, several glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been approved to treat people with type 2 diabetes. These agents are considered for use at the same point in the treatment paradigm as basal insulins. A comprehensive comparison of these drug classes, therefore, can help inform treatment decisions. This systematic review and meta-analysis assessed the clinical efficacy and safety of GLP-1 RAs compared with basal insulins. MATERIALS AND METHODS: MEDLINE, EMBASE, CENTRAL and PubMed databases were searched...
October 7, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27456750/efficacy-and-safety-of-once-weekly-glucagon-like-peptide-1-receptor-agonists-compared-with-exenatide-and-liraglutide-in-type-2-diabetes-a-systemic-review-of-randomised-controlled-trials
#2
REVIEW
X Xue, Z Ren, A Zhang, Q Yang, W Zhang, F Liu
BACKGROUND: Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promising results in the treatment of type 2 diabetes. Herein, we compared the efficacy and safety of once-weekly GLP-1RAs with exenatide and liraglutide separately. METHODS: We systematically surveyed the pertinent literature using various databases. The randomised controlled trials that compared once-weekly GLP-1RAs with exenatide and liraglutide in type 2 diabetes were included...
August 2016: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/27436599/a-post-hoc-analysis-of-long-term-prognosis-after-exenatide-treatment-in-patients-with-st-segment-elevation-myocardial-infarction
#3
Kasper Kyhl, Jacob Lønborg, Niels Vejlstrup, Henning Kelbæk, Steffen Helqvist, Lene Holmvang, Erik Jørgensen, Kari Saunamäki, Hans Erik Bøtker, Peter Clemmensen, Lars Køber, Marek Treiman, Thomas Engstrøm
AIMS: We aimed to assess the effect of exenatide treatment as an adjunct to primary percutaneous coronary intervention (PCI) on long-term clinical outcome. METHODS AND RESULTS: We performed a post hoc analysis in 334 patients with a first STEMI included in a previous study randomised to exenatide (n=175) or placebo (n=159) as an adjunct to primary PCI. The primary endpoint was a composite of all-cause mortality and admission for heart failure during a median follow-up of 5...
July 20, 2016: EuroIntervention
https://www.readbyqxmd.com/read/27363489/glp-1-analogues-for-neuroprotection-after-out-of-hospital-cardiac-arrest-study-protocol-for-a-randomized-controlled-trial
#4
Sebastian Wiberg, Christian Hassager, Jakob Hartvig Thomsen, Martin Frydland, Dan Eik Høfsten, Thomas Engstrøm, Lars Køber, Henrik Schmidt, Jacob Eifer Møller, Jesper Kjaergaard
BACKGROUND: Attenuating the neurological damage occurring after out-of-hospital cardiac arrest is an ongoing research effort. This dual-centre study investigates the neuroprotective effects of the glucagon-like-peptide-1 analogue Exenatide administered within 4 hours from the return of spontaneous circulation to comatose patients resuscitated from out-of-hospital cardiac arrest. METHODS/DESIGN: This pilot study will randomize a total of 120 unconscious patients with sustained return of spontaneous circulation after out-of-hospital cardiac arrest undergoing targeted temperature management in a blinded one-to-one fashion to a 6-hour and 15-minute infusion of either Exenatide or placebo...
2016: Trials
https://www.readbyqxmd.com/read/27158818/efficacy-and-acceptability-of-glycemic-control-of-glucagon-like-peptide-1-receptor-agonists-among-type-2-diabetes-a-systematic-review-and-network-meta-analysis
#5
Zhixia Li, Yuan Zhang, Xiaochi Quan, Zhirong Yang, Xiantao Zeng, Linong Ji, Feng Sun, Siyan Zhan
OBJECTIVE: To synthesize current evidence of the impact of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on hypoglycemia, treatment discontinuation and glycemic level in patients with type 2 diabetes. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Literature search (Medline, Embase, the Cochrane library), website of clinical trial, bibliographies of published systematic reviews. ELIGIBILITY CRITERIA: Randomized controlled trials with available data comparing GLP-1 RAs with placebo or traditional anti-diabetic drugs in patients with type 2 diabetes...
2016: PloS One
https://www.readbyqxmd.com/read/25678952/efficacy-and-tolerability-of-glucagon-like-peptide-1-receptor-agonists-in-patients-with-type-2-diabetes-mellitus
#6
REVIEW
Kira B Harris, Delilah J McCarty
Glucagon-like peptide-1 (GLP-1) has been evaluated for use in the treatment of type 2 diabetes mellitus (T2DM) due to its role in glucose regulation. Four GLP-1 receptor agonists (RAs) are currently indicated for T2DM in the USA. Exenatide and liraglutide are short-acting and require twice-daily and daily dosing, respectively. Two longer acting agents, exenatide long-acting release (LAR) and albiglutide, were formulated to allow for once-weekly dosing. All four GLP-1 RAs have demonstrated reductions in hemoglobin A1c, fasting blood glucose, and body weight both as monotherapy and in combination with first- and second-line diabetes agents including metformin, sulfonylureas, thiazolidinediones, and insulin...
February 2015: Therapeutic Advances in Endocrinology and Metabolism
https://www.readbyqxmd.com/read/25561121/-effects-of-exenatide-lar-in-type-2-diabetes-mellitus-and-obesity
#7
Roberto Sierra Poyatos, Pilar Riobó Serván, Clotilde Vázquez Martínez
INTRODUCTION: GLP-1 analogs have been shown to be an effective treatment of type 2 diabetes mellitus (DM-2) and obesity. OBJECTIVES: Evaluate the efficacy of exenatide LAR on weight loss, glycemic control, blood pressure (BP) and lipid profile, in DM-2 and obesity. MATERIAL AND METHODS: Retrospective study of patients treated with exenatide LAR for 6 months. Demographic data (age, gender), anthropometric, fasting glucose, glycated hemoglobin (HbA1c), blood pressure and lipid profile were collected at baseline and at 6 months after treatment...
2015: Nutrición Hospitalaria: Organo Oficial de la Sociedad Española de Nutrición Parenteral y Enteral
https://www.readbyqxmd.com/read/25331711/pharmacokinetics-and-clinical-use-of-incretin-based-therapies-in-patients-with-chronic-kidney-disease-and-type%C3%A2-2-diabetes
#8
REVIEW
André J Scheen
The prevalence of chronic kidney disease (CKD) of stages 3-5 (glomerular filtration rate [GFR] <60 mL/min) is about 25-30 % in patients with type 2 diabetes mellitus (T2DM). While most oral antidiabetic agents have limitations in patients with CKD, incretin-based therapies are increasingly used for the management of T2DM. This review analyses (1) the influence of CKD on the pharmacokinetics of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists; and (2) the efficacy/safety profile of these agents in clinical practice when prescribed in patients with both T2DM and CKD...
January 2015: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/24923102/-bydureon-first-once-weekly-glp-1-receptor-agonist-exenatide-lar
#9
COMPARATIVE STUDY
A J Scheen
Bydureon is a new galenic formulation (long-acting release) of exenatide, the first agonist of Glucagon-Like Peptide-1 (GLP-1) receptors having been commercialized for the management of type 2 diabetes. The microsphere technology permits a prolonged absorption of exenatide from the subcutaneous depot, which allows one injection per week instead of two injections per day with the initial formulation of exenatide (Byetta). The clinical development programme DURATION showed that exenatide 2 mg once weekly more markedly reduces glycated haemoglobin (HbA(1c)), with a similar weight loss but a better digestive tolerance profile (less nausea and vomiting after treatment initiation), compared with the twice daily 10 microg exenatide...
April 2014: Revue Médicale de Liège
https://www.readbyqxmd.com/read/24584550/impact-of-acute-hyperglycemia-on-myocardial-infarct-size-area-at-risk-and-salvage-in-patients-with-stemi-and-the-association-with-exenatide-treatment-results-from-a-randomized-study
#10
RANDOMIZED CONTROLLED TRIAL
Jacob Lønborg, Niels Vejlstrup, Henning Kelbæk, Lars Nepper-Christensen, Erik Jørgensen, Steffen Helqvist, Lene Holmvang, Kari Saunamäki, Hans Erik Bøtker, Won Yong Kim, Peter Clemmensen, Marek Treiman, Thomas Engstrøm
Hyperglycemia upon hospital admission in patients with ST-segment elevation myocardial infarction (STEMI) occurs frequently and is associated with adverse outcomes. It is, however, unsettled as to whether an elevated blood glucose level is the cause or consequence of increased myocardial damage. In addition, whether the cardioprotective effect of exenatide, a glucose-lowering drug, is dependent on hyperglycemia remains unknown. The objectives of this substudy were to evaluate the association between hyperglycemia and infarct size, myocardial salvage, and area at risk, and to assess the interaction between exenatide and hyperglycemia...
July 2014: Diabetes
https://www.readbyqxmd.com/read/22496084/exenatide-reduces-final-infarct-size-in-patients-with-st-segment-elevation-myocardial-infarction-and-short-duration-of-ischemia
#11
RANDOMIZED CONTROLLED TRIAL
Jacob Lønborg, Henning Kelbæk, Niels Vejlstrup, Hans Erik Bøtker, Won Yong Kim, Lene Holmvang, Erik Jørgensen, Steffen Helqvist, Kari Saunamäki, Christian Juhl Terkelsen, Mikkel Malby Schoos, Lars Køber, Peter Clemmensen, Marek Treiman, Thomas Engstrøm
BACKGROUND: Exenatide has been demonstrated to be cardioprotective as an adjunct to primary percutaneous coronary intervention in patients with ST-segment-elevation myocardial infarction (STEMI). The aim of the post hoc analysis study was to evaluate the effect of exenatide in relation to system delay, defined as time from first medical contact to first balloon. METHODS AND RESULTS: Patients with STEMI and Thrombolysis In Myocardial Infarction flow 0/1 were randomly assigned to intravenous exenatide or placebo continuous infusion...
April 2012: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/22471248/glycaemic-efficacy-of-glucagon-like-peptide-1-receptor-agonists-and-dipeptidyl-peptidase-4-inhibitors-as-add-on-therapy-to-metformin-in-subjects-with-type-2-diabetes-a-review-and-meta-analysis
#12
REVIEW
C F Deacon, E Mannucci, B Ahrén
AIMS: During recent years, two strategies of incretin-based therapy [glucagon-like peptide-1 (GLP-1) receptor agonism and dipeptidyl peptidase-4 (DPP-4) inhibition] have entered the market for pharmacological management of type 2 diabetes. A main indication for this therapy is as add-on to on-going metformin therapy in subjects with type 2 diabetes who have insufficient glycaemic control with metformin alone. The aim of this study was to compare improvements in glycaemic control and changes in body weight, as well as adverse events, in comparable studies with incretin-based therapy as add-on to metformin...
August 2012: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/22432846/glp-1-agonists-exenatide-and-liraglutide-a-review-about-their-safety-and-efficacy
#13
REVIEW
Giuseppe Derosa, Pamela Maffioli
Recently incretin-based therapies have been developed in the clinical practice, this class includes both the dipeptidyl peptidase-4 (DPP-4) inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin), and the glucagon-like peptide- 1 (GLP-1) receptor agonists [exenatide, exenatide long acting release (LAR) and liraglutide]. In particular exenatide and liraglutide have structural similarity and bind to the GLP-1 receptor, displaying a similar broad range of activities relevant to improving glycemic control, including stimulation of insulin secretion and reduction of glucagon secretion, both in a glucose-dependent manner...
August 2012: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/22234463/glp-1-receptor-agonists-and-the-thyroid-c-cell-effects-in-mice-are-mediated-via-the-glp-1-receptor-and-not-associated-with-ret-activation
#14
Lars Wichmann Madsen, Jeffrey A Knauf, Carsten Gotfredsen, Andrew Pilling, Ingrid Sjögren, Søren Andersen, Lene Andersen, Anne Sietske de Boer, Katia Manova, Afsar Barlas, Sushil Vundavalli, Niels C Berg Nyborg, Lotte Bjerre Knudsen, Anne Marie Moelck, James A Fagin
Liraglutide and exenatide are glucagon-like peptide receptor (GLP-1R) agonists used in the treatment of type 2 diabetes. Both molecules have been associated with the development of thyroid C-cell tumors after lifetime exposure in rodents. Previously, it has been reported that these tumors are preceded by increased plasma calcitonin and C-cell hyperplasia. We can now document that the murine C-cell effects are mediated via GLP-1R. Thus, 13 wk of continuous exposure to GLP-1R agonists was associated with marked increases in plasma calcitonin and in the incidence of C-cell hyperplasia in wild-type mice...
March 2012: Endocrinology
https://www.readbyqxmd.com/read/22232377/clinical-efficacy-and-safety-of-once-weekly-glucagon-like-peptide-1-agonists-in-development-for-treatment-of-type-2-diabetes-mellitus-in-adults
#15
REVIEW
Maria Tzefos, Kira Harris, Adriane Brackett
OBJECTIVE: To review pharmacologic, pharmacokinetic, efficacy, and safety data of once-weekly glucagon-like peptide-1 (GLP-1) agonists exenatide long-acting release (LAR), albiglutide, and taspoglutide in treatment of type 2 diabetes mellitus (T2DM). DATA SOURCES: A MEDLINE search (1966-August 2011) was conducted using the following key words: type 2 diabetes mellitus, glucagon-like peptide-1 agonists once weekly, glucagon-like peptide-1 agonists, exenatide LAR, albiglutide, and taspoglutide...
January 2012: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/21920963/exenatide-reduces-reperfusion-injury-in-patients-with-st-segment-elevation-myocardial-infarction
#16
RANDOMIZED CONTROLLED TRIAL
Jacob Lønborg, Niels Vejlstrup, Henning Kelbæk, Hans Erik Bøtker, Won Yong Kim, Anders B Mathiasen, Erik Jørgensen, Steffen Helqvist, Kari Saunamäki, Peter Clemmensen, Lene Holmvang, Leif Thuesen, Lars Romer Krusell, Jan S Jensen, Lars Køber, Marek Treiman, Jens Juul Holst, Thomas Engstrøm
AIMS: Exenatide, a glucagon-like-peptide-1 analogue, increases myocardial salvage in experimental settings with coronary occlusion and subsequent reperfusion. We evaluated the cardioprotective effect of exenatide at the time of reperfusion in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). METHODS AND RESULTS: A total of 172 patients with STEMI and Thrombolysis in Myocardial Infarction flow 0/1 were randomly assigned to exenatide or placebo (saline) intravenously...
June 2012: European Heart Journal
https://www.readbyqxmd.com/read/21663496/glp-1-receptor-agonists-and-hba1c-target-of-7-in-type-2-diabetes-meta-analysis-of-randomized-controlled-trials
#17
COMPARATIVE STUDY
K Esposito, C Mosca, C Brancario, P Chiodini, A Ceriello, D Giugliano
OBJECTIVE: Glucagon-like peptide-1 (GLP-1) receptor agonists are available for the treatment of type 2 diabetes. We assessed the efficacy of exenatide and liraglutide to reach the HbA(1c) target of <7% in people with type 2 diabetes. RESEARCH DESIGN AND METHODS: We conducted an electronic search for randomized controlled trials (RCTs) involving GLP-1 agonists through September 2010. RCTs were included if they lasted at least 12 weeks, included 30 patients or more, and reported the proportion of patients reaching the HbA(1c) target of <7%...
August 2011: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/17353504/effects-of-once-weekly-dosing-of-a-long-acting-release-formulation-of-exenatide-on-glucose-control-and-body-weight-in-subjects-with-type-2-diabetes
#18
RANDOMIZED CONTROLLED TRIAL
Dennis Kim, Leigh MacConell, Dongliang Zhuang, Prajakti A Kothare, Michael Trautmann, Mark Fineman, Kristin Taylor
OBJECTIVE: In patients with type 2 diabetes, exenatide reduces A1C, postprandial and fasting glucose, and weight. In this study we investigated the effects of continuous exenatide administration from a long-acting release (LAR) formulation. RESEARCH DESIGN AND METHODS: In this randomized, placebo-controlled phase 2 study, exenatide LAR (0.8 or 2.0 mg) was administered subcutaneously once weekly for 15 weeks to subjects with type 2 diabetes (n = 45) suboptimally controlled with metformin (60%) and/or diet and exercise (40%): 40% female, A1C (mean +/- SD) 8...
June 2007: Diabetes Care
https://www.readbyqxmd.com/read/16625817/obesity-drugs-in-clinical-development
#19
REVIEW
Jason C G Halford
A number of anti-obesity drugs are currently undergoing clinical development. These include: (i) centrally-acting drugs, such as the noradrenergic and dopaminergic reuptake inhibitor radafaxine, the endocannabinoid antagonist rimonabant, the selective serotonin 5-HT2c agonist APD-356, and oleoyl-estrone; (ii) drugs that target peripheral episodic satiety signals, such as glucagon-like peptide-1 (exenatide, exenatide-LAR and liraglutide), peptide YY (intranasal PYY3-36 and AC-162325) and amylin (pramlintide); (iii) drugs that block fat absorption, such as the novel lipase inhibitors cetilistat and GT-389255; and (iv) a human growth hormone fragment (AOD-9604) that increases adipose tissue breakdown...
April 2006: Current Opinion in Investigational Drugs
https://www.readbyqxmd.com/read/15915337/dose-response-for-glycaemic-and-metabolic-changes-28-days-after-single-injection-of-long-acting-release-exenatide-in-diabetic-fatty-zucker-rats
#20
B R Gedulin, P Smith, K S Prickett, M Tryon, S Barnhill, J Reynolds, L L Nielsen, D G Parkes, A A Young
AIMS/HYPOTHESIS: Exenatide (exendin-4) injected subcutaneously twice daily reduces glycaemic deterioration in diabetic fatty Zucker (ZDF) rats and reduces HbA1c in humans with type 2 diabetes. Because tachyphylaxis may develop with continuous peptide exposure, we examined the activity of a long-acting-release (LAR) formulation of exenatide on HbA1c, insulin sensitivity and beta cell secretion in ZDF rats. METHODS: Single subcutaneous injections of a poly-lactide-glycolide microsphere suspension (3% peptide) containing 0, 1, 10, 100, 1,000, 3,000 or 9,000 mug exenatide were administered to 9-week-old ZDF rats with matched initial HbA1c values (n=7 rats/group)...
July 2005: Diabetologia
keyword
keyword
19281
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"